Can CAR-T MM(multiple myeloma) be cured

Can CAR-T MM(multiple myeloma) be cured

CAR-T therapy targeting antigens related to multiple myeloma has brought new hope for curing this disease in clinical medicine. Recent research findings have shown that this treatment strategy has a remarkable efficacy rate, but there are still significant drawbacks that cannot be ignored.

Can CAR-T cure multiple myeloma?

From the current medical perspective, it is still uncertain whether CAR-T can cure multiple myeloma.

The main reasons are the toxicities and limitations associated with CAR-T therapy, including off-tumor toxicities, antigen escape, suboptimal activation, and poor persistence of CAR-T cells.

I. CAR-T therapy toxicities can be classified into two categories: one is the consequence of T-cell recognition and activation against malignant myeloma cells, as well as uncontrolled high levels of cytokines, which often leads to on-target, off-tumor toxicities; the second is the toxicity resulting from the specific binding of CAR-T cells to antigens expressed on normal cells.

II. The high relapse rate of CAR-T is also a major obstacle to curing multiple myeloma, mainly due to the presence of a substantial number of tumor subclones in myeloma patients, making it difficult to achieve complete treatment.

As the number of patients receiving CAR-T therapy increases, these issues have emerged. To expand the prospects of recovery with CAR-T, it is necessary to more comprehensively address these drawbacks.

Content Source:多发性骨髓瘤病友会